Biogen gets mixed decision at FDA AdComm on failed ALS drug as experts back
Biogen gets mixed decision at FDA AdComm on failed ALS drug as experts back conditional, not full, approval FierceBiotechBiogen Stock Pops — But Ionis Stock Dips — On Mixed FDA View For ALS Drug Investor's Business DailyPharmalittle:…